Rein Therapeutics, Inc. (RNTX) intrinsic value & 10-year financials
Rein Therapeutics, Inc. (RNTX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue reached to $0, with an average return on invested capital of -94.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.59
- Market cap
- $15.0M
- Revenue (FY2025)
- $0
- ROIC (10-yr avg)
- -94.5%
- Free cash flow (FY2025)
- —
RNTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$49.9M | -$1.96 | — | — | -140.0% |
| FY2024 | $0 | -$62.9M | -$3.51 | — | — | -207.4% |
| FY2023 | $0 | -$15.7M | -$0.85 | — | — | -127.6% |
| FY2022 | $0 | -$27.3M | -$1.50 | — | — | -68.5% |
| FY2021 | $0 | -$26.2M | -$1.47 | -$23.9M | — | -65.9% |
| FY2020 | $0 | -$21.2M | — | -$20.5M | — | -133.8% |
| FY2019 | $0 | -$29.4M | — | -$26.6M | — | -195.5% |
| FY2018 | $0 | -$31.5M | — | -$32.3M | — | -94.7% |
| FY2017 | $0 | -$22.6M | — | -$20.7M | — | 71.9% |
| FY2016 | $0 | -$18.1M | — | — | — | 16.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Rein Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Rein Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -54.6% ROIC.
Rein Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Rein Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.